288 related articles for article (PubMed ID: 29949442)
1. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP
Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442
[TBL] [Abstract][Full Text] [Related]
2. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Armand P; Shipp MA; Ribrag V; Michot JM; Zinzani PL; Kuruvilla J; Snyder ES; Ricart AD; Balakumaran A; Rose S; Moskowitz CH
J Clin Oncol; 2016 Nov; 34(31):3733-3739. PubMed ID: 27354476
[TBL] [Abstract][Full Text] [Related]
3. Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?
Sabanathan D; Park JJ; Marquez M; Francisco L; Byrne N; Gurney H
Oncologist; 2017 Dec; 22(12):1470-1477. PubMed ID: 29146617
[TBL] [Abstract][Full Text] [Related]
4. Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
Friedman CF; Postow MA
Curr Oncol Rep; 2016 Apr; 18(4):21. PubMed ID: 26922327
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab in classical Hodgkin's lymphoma.
Maly J; Alinari L
Eur J Haematol; 2016 Sep; 97(3):219-27. PubMed ID: 27147112
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of immune checkpoint inhibition in malignant lymphoma.
Hude I; Sasse S; Engert A; Bröckelmann PJ
Haematologica; 2017 Jan; 102(1):30-42. PubMed ID: 27884973
[TBL] [Abstract][Full Text] [Related]
7. Real world effectiveness and safety of nivolumab in patients with relapsed or refractory classical hodgkin lymphoma.
Lorente Fernández L; Romero Domínguez S; Albert Marí A; Núñez Benito E; López Briz E; Poveda Andrés JL
Farm Hosp; 2024 Jun; ():. PubMed ID: 38839541
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
Formenti SC; Rudqvist NP; Golden E; Cooper B; Wennerberg E; Lhuillier C; Vanpouille-Box C; Friedman K; Ferrari de Andrade L; Wucherpfennig KW; Heguy A; Imai N; Gnjatic S; Emerson RO; Zhou XK; Zhang T; Chachoua A; Demaria S
Nat Med; 2018 Dec; 24(12):1845-1851. PubMed ID: 30397353
[TBL] [Abstract][Full Text] [Related]
9. STAT3 Expression and Its Correlation with PD-L1 Expression in Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma at Dr. Saiful Anwar Regional Public Hospital in Malang, Indonesian Population.
Hambalie AO; Norahmawati E; Endharti AT; Retnani DP; Rahmadiani N
Adv Hematol; 2024; 2024():7989996. PubMed ID: 38817669
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update.
Gellrich FF; Schmitz M; Beissert S; Meier F
J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31947592
[TBL] [Abstract][Full Text] [Related]
11. Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure.
Longley J; Johnson PWM
Hematol Oncol; 2021 Jun; 39 Suppl 1():39-45. PubMed ID: 34105815
[TBL] [Abstract][Full Text] [Related]
12. Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review.
Chicas-Sett R; Morales-Orue I; Rodriguez-Abreu D; Lara-Jimenez P
Clin Transl Radiat Oncol; 2018 Feb; 9():5-11. PubMed ID: 29594244
[TBL] [Abstract][Full Text] [Related]
13. Complications of Brentuximab Therapy in Patients with Hodgkin's Lymphoma and Concurrent Autoimmune Pathology-A Case Series.
Preda OD; Bădeliță S; Ursuleac I; Irimia RM; Balanica S; Cojocaru M; Cotruta C; Dobrea C; Coriu D
Hematol Rep; 2024 May; 16(2):299-307. PubMed ID: 38804283
[No Abstract] [Full Text] [Related]
14. Immune Checkpoint Inhibitor Use in Sepsis: Monitoring Immune Checkpoint Inhibitor Toxicity.
Suresh K; D'Alessio F
Crit Care Med; 2019 Sep; 47(9):e788. PubMed ID: 31415322
[No Abstract] [Full Text] [Related]
15. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials.
Menshawy A; Eltonob AA; Barkat SA; Ghanem A; Mniesy MM; Mohamed I; Abdel-Maboud M; Mattar OM; Elfil M; Bahbah EI; Elgebaly A
Melanoma Res; 2018 Oct; 28(5):371-379. PubMed ID: 29957656
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.
Afzal MZ; Mercado RR; Shirai K
J Immunother Cancer; 2018 Jul; 6(1):64. PubMed ID: 29966520
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
[TBL] [Abstract][Full Text] [Related]
19. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy-based combinations: an update.
Fucà G; de Braud F; Di Nicola M
Curr Opin Oncol; 2018 Sep; 30(5):345-351. PubMed ID: 29994900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]